Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

NCT06420167 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT06420167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
July 11, 2024
Completion date
April 30, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal al amyloidosis